If BP saw value they would not pass because of some "business model" concept.
They are continually buying into new technology that replaces existing agents. If one does not, they get left behind by the others that do.
There are also BPs that have little to no oncology products and could be interested, Gilead is a good example.
It is fair to argue that BP does not care about patient health, But they do care about owning blockbusters, a lot more than aging chemo that makes little in profits due to generic competition. And they care care less about the treatment being personalized. They would sell cow DCs to people if they thought they make money.
News 
Market Data 
Discover 
AI
